RT Journal Article
SR Electronic
T1 Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP i104
OP i108
DO 10.1136/ard.2010.140145
VO 70
IS Suppl 1
A1 Sergei I Grivennikov
A1 Michael Karin
YR 2011
UL http://ard.bmj.com/content/70/Suppl_1/i104.abstract
AB Up to 20% of all cancers arise in association with chronic inflammation and most, if not all, solid tumours contain inflammatory infiltrates. Immune cells have a broad impact on tumour initiation, growth and progression and many of these effects are mediated by proinflammatory cytokines. Among these cytokines, the pro-tumourogenic function of tumour necrosis factor (TNF) and interleukin 6 (IL-6) is well established. The role of TNF and IL-6 as master regulators of tumour-associated inflammation and tumourigenesis makes them attractive targets for adjuvant treatment in cancer